Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa (Nasdaq: KNSA) launched Heart’s Home, a targeted Direct-to-Consumer TV campaign for ARCALYST (rilonacept) on April 8, 2026. The campaign targets patients with recurrent pericarditis (about 40,000 U.S. patients yearly), is live on connected TV and streaming, and includes digital and social components. ARCALYST is the first-and-only FDA approved therapy to treat recurrent pericarditis and reduce recurrence risk in patients aged 12+, administered as a weekly subcutaneous injection blocking IL-1α and IL-1β.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 p.m. ET. A live webcast will be available via the Investors section of Kiniksa's website, with a replay posted within approximately 48 hours.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q4 2025 ARCALYST net product revenue of $202.1M and full-year 2025 ARCALYST revenue of $677.6M, a 62% year-over-year increase. The company expects 2026 ARCALYST revenue of $900–$920M and plans KPL-387 Phase 2 data in 2H 2026 and a KPL-1161 Phase 1 start by end of 2026. Cash rose by $170.4M to $414.1M and full-year 2025 net income was $59.0M.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET. A live webcast will be available via the Investors & Media section of the company's website, and a replay will be posted approximately 48 hours after the event. Telephone participants must register to receive dial-in details and a unique passcode.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported unaudited ARCALYST net product revenue of $677.5M in 2025, ~62% year-over-year growth, and expects 2026 ARCALYST revenue of $900M–$920M. Gross-to-net was 8.4% in 2025 vs 9.8% in 2024, reflecting Inflation Reduction Act impacts and fourth-quarter reserve adjustments. As of Dec 31, 2025, cash, cash equivalents and short-term investments totaled $414.1M (no debt), up $170.4M in 2025 (unaudited). Approximately 18% of 14,000 multiple-recurrence patients were on ARCALYST at year end; >4,150 prescribers have written ARCALYST prescriptions. Clinical milestones: KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. PT (5:15 p.m. ET). A live webcast will be available via the company's Investors website and a replay will be posted approximately 48 hours after the event.
Investors can access the webcast at www.kiniksa.com.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. GMT (9:30 a.m. ET). Management's presentation will be webcast live and accessible via the Investors section of Kiniksa's website at www.kiniksa.com. A replay will be posted on the company website approximately 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q3 2025 results and portfolio updates on October 28, 2025. ARCALYST net product revenue was $180.9M in Q3, a 61% year-over-year increase, leading Kiniksa to raise 2025 ARCALYST guidance to $670M–$675M (from $625M–$640M). The company reported net income of $18.4M in Q3 versus a net loss of $12.7M in Q3 2024. Cash, cash equivalents and short-term investments rose by $44.3M to $352.1M as of September 30, 2025, with no debt.
Pipeline news: FDA granted Orphan Drug Designation to KPL-387 for pericarditis; Phase 2 dose-finding data expected in H2 2026, then pivotal start. KPL-1161 remains in IND-enabling work.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report third quarter 2025 results and recent portfolio execution on Tuesday, October 28, 2025 at 8:30 a.m. ET. The company will host a conference call and live webcast accessible via the Investors & Media section of www.kiniksa.com.
Participants can register to join by telephone and will receive a confirmation email with dial-in details, a unique passcode, and registrant ID. A replay will be available on Kiniksa’s website approximately 48 hours after the event.
Kiniksa (Nasdaq: KNSA) announced that the U.S. FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, including recurrent pericarditis, on October 17, 2025.
KPL-387 is an independently developed monoclonal antibody that binds IL-1R1, inhibiting signaling of IL-1α and IL-1β. The company highlights potential dosing as a single monthly subcutaneous self-injection in a liquid formulation. Data from the Phase 2 dose-focusing portion of the Phase 2/3 recurrent pericarditis trial are expected in the second half of 2026.